Active Ingredient History
Adavosertib is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca. It is being investigated as a treatment for pancreatic cancer with phase 1 trial. University of Michigan researchers are as of 2019 planning a phase 2 study. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Endometrioid (Phase 1)
Endometrial Neoplasms (Phase 1)
Esophageal Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Lymphoma (Phase 2)
Multiple Myeloma (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Stomach Neoplasms (Phase 1)
Uterine Cervical Neoplasms (Phase 1)
Uterine Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue